Abstract 192P
Background
Neoadjuvant chemotherapy is the best option for most epithelial ovarian cancers as they present in stage III & IV.The important determinants of survival in ovarian cancer include complete cytoreduction and response to platinum based chemotherapy . HE4, a novel biomarker was found to be better predictor of optimal cytoreduction and platinum sensitivity compared to CA 125 which has low sensitivity and specificity in premenopausal women. This study is done to assess the role of serum marker HE4 in predicting response to chemotherapy in epithelial ovarian cancer.
Methods
This is a prospective observational study of 39 patients in the age group 25-75yrs with newly diagnosed epithelial ovarian cancer/primary peritoneal carcinoma planned for neo adjuvant chemotherapy. Patients with renal failure and other cancers which can cause HE4 elevation were excluded. Tumour markers CA125 and HE4 were measured at baseline, before each cycle of chemotherapy and before surgery. Imaging with CECT abdomen was done at the end of neo adjuvant chemotherapy. The prediction of response by the tumour markers were assessed.
Results
Most patients were postmenopausal with high grade serous adenocarcinoma histology, in advanced stage(FIGO 3 or 4). Tumour markers did not predict radiological outcomes. Optimal cytoreduction(R0-≤ 1cm residual disease) was achieved in 66.7%. Neither CA125 nor its reduction with chemotherapy was predictive of surgical outcome. HE4 at the end of NACT and its reduction with chemotherapy was predictive of optimal cytoreduction. HE4 cut off of 275pmol/L at the end of NACT had 77% sensitivity and 85% specificity to predict poor surgical outcome. Reduction in HE4 with chemotherapy was a predictor of pathological response. Table: 192P
| Baseline | Cycle 1 | Cycle 2 | Cycle 3 | End of NACT | ||||||
| Marker | CA 125 | HE 4 | CA 125 | HE 4 | CA 125 | HE 4 | CA 125 | HE 4 | CA 125 | HE 4 |
| %Reduction (R+) | 43 | 30 | 73 | 55 | 83 | 66 | 86 | 71 | ||
| %Reduction (R0) | 48 | 48 | 75 | 73 | 86 | 86 | 88 | 88 | ||
| p-value | >0.05 | <0.01 | >0.05 | <0.01 | >0.05 | <0.01 | >0.05 | <0.01 | ||
| R+ | 1924.95 | 2121.6 | 911.45 | 1321 | 281.23 | 833.6 | 168.45 | 580.3 | 164.33 | 522.0 |
| R0 | 1470.66 | 2366.8 | 813.34 | 1147.7 | 330.1 | 562.5 | 153.73 | 287.1 | 126.22 | 172.3 |
| p-value | >0.05 | >0.05 | >0.05 | >0.05 | >0.05 | >0.05 | >0.05 | <0.05 | >0.05 | <0.01 |
Conclusions
HE4 is a better predictor of response to therapy in patients undergoing neo adjuvant chemotherapy. HE4 value at the end of NACT and percentage reduction with each cycle can predict optimal cytoreduction after neo adjuvant chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sarada Planjery.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
265P - Tumor-agonistic genomic profiling
Presenter: Naomi Hayashi
Session: Poster viewing 03
266P - Dynamic mutation profiles of Chinese patients with EGFR T790M advanced NSCLC receiving osimertinib
Presenter: Xuchao Zhang
Session: Poster viewing 03
267P - Genomic landscape of non-small cell lung cancer (NSCLC) in India using circulating tumor DNA (ctDNA) in clinical practice
Presenter: Amit Rauthan
Session: Poster viewing 03
269P - MET alterations in EGFR mutated NSCLC: A lesser known evil
Presenter: Mansi Sharma
Session: Poster viewing 03
271P - Prospective study on toxicity profile of immunotherapy in a Indian population: A real-world experience
Presenter: Kaushik R
Session: Poster viewing 03